FDA gives new Biogen Alzheimer's treatment priority status
![Photo: BRIAN SNYDER/REUTERS / X90051](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13828790.ece/ALTERNATES/schema-16_9/doc7k4tmh7imo810h3ugoe1.jpg)
The FDA has granted US-based Biogen and Japanese firm Eisai priority status for another Alzheimer’s treatment, lecanemab.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novo Nordisk recruits 500 people for Alzheimer's trial
For subscribers